Cipla will focus on driving its products portfolio through its own sales force team, while S&D Pharma will physically distribute the basket of products
New Delhi: Indian generic drug maker Cipla Ltd said on Monday it has entered into a collaboration with UK-based S&D Pharma to sell its products in the Czech Republic and Slovakia.
Cipla will focus on driving its products portfolio, including respiratory products, through its own sales force team managed by the company’s commercial head. S&D Pharma will physically distribute the basket of products.
Cipla will also launch its respiratory inhaler Salmeterol-Fluticasone fixed combination in these markets under the name Fullhale, once regulatory and reimbursement approvals are in place.
UK-based S&D Pharma represents global pharmaceutical companies and manages the promotion and distribution of their products in Central Europe.
The development comes at a time when Cipla is eyeing new markets and increasing its manufacturing capacity. Last week, the company announced acquisition of two manufacturing units, one in Goa and the other in Maharashtra, from its contract manufacturer Okasa for Rs100.93 crore.
Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.
Never miss a story! Stay connected and informed with Mint.
our App Now!!